Podcasts about life sciences

In the late 1980s, a child exposed to fallout from the Chernobyl disaster lay in a hospital bed while doctors told his family there were no clear answers and no reliable path forward. Decades later, that same child, Yan Leyfman, walks into exam rooms as a hematology oncology fellow, expected to deliver clarity inside a system that still runs on delay, uncertainty, and institutional self preservation.This episode traces the throughline from early life shaped by radiation exposure and hospice level uncertainty to a career inside academic medicine, translational research, and oncology media. Yan built his identity around survival and usefulness, moving from patient to physician while carrying the memory of what it feels like to sit on the other side of the table. He helped launch MedNews Week during the COVID crisis to push back on misinformation and expand access to medical knowledge, stepping into a public role while still in training.The conversation stays grounded in the friction between personal narrative and system reality. Clinical training demands efficiency, hierarchy, and emotional distance. Cancer care demands time, clarity, and human connection. Those forces collide in real patient encounters where prior authorization delays, insurance barriers, and fragmented care pathways shape outcomes as much as any treatment protocol.Yan speaks openly about mentorship, belonging, and the drive to make meaning out of survival. The discussion pushes further into what the healthcare system actually rewards, what it quietly strips away, and how quickly empathy can erode under institutional pressure. The episode also examines the role of medical media, where education, industry influence, and narrative control often blur together.This is a conversation about identity under construction, about what happens when someone who remembers powerlessness steps into a role that carries authority, and about whether that memory can survive long enough to change anything.RELATED LINKSYan Leyfman on LinkedInYan Leyfman on InstagramSurviving ChernobylFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Matthew Zachary is a brain cancer survivor, healthcare advocate, founder of Stupid Cancer and We the Patients, and host of Out of Patients. In April 2026, he returned to the stage at Merkin Hall near Lincoln Center for his first solo public piano concert in almost 22 years while launching his debut book, We the Patients: Understanding, Navigating, and Surviving America's Healthcare Nightmare.What unfolded became far larger than a concert.Over 2 hours, survivors, clinicians, advocates, nonprofit founders, journalists, pharmaceutical sponsors, and healthcare insiders gathered in one room to reflect on 30 years of survivorship, institutional failure, accidental advocacy, and the emotional afterlife of cancer. The evening moved through original piano performances, live chapter readings, and deeply personal conversations about infertility, disability, financial toxicity, insurance denials, grief, burnout, and what happens when patients spend decades navigating systems designed around transactions instead of continuity.Guests including Wendell Potter, Maimah Karmo, Craig Lustig, Shelly Fuld Nasso, Tamika Felder, and others reflected on how the modern cancer advocacy movement emerged largely because patients built parallel systems where healthcare infrastructure failed to meet human needs. The conversation explored how prior authorization, reimbursement incentives, administrative fragmentation, and institutional distrust continue shaping the patient experience across oncology and survivorship.The performance also marked a deeply personal milestone. After brain cancer compromised his left hand at age 21, Zachary spent 6 months rehabilitating both hands to return to public performance for the first time in over 2 decades. The result became part concert, part civic gathering, and part historical record of a generation of survivors who refused to disappear quietly.RELATED LINKSMZLIVE Official WebsiteMZLIVE YouTube VideoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if a single unplugged power cord nearly derailed a top biotech leader's story—and ended up launching an episode packed with innovation, real connection, and a peek inside Philadelphia's hidden biotech gems? In this lively, uplifting conversation, Lou Diamond welcomes Robert Christmas, the connector behind the Pennsylvania Biotechnology Center and the Union League's Life Science Affinity Club. They dive into the unexpected journeys that lead scientists to solve some of humanity's biggest problems, the secrets behind Philly's “pharma belt,” and the power of community-driven innovation. Along the way, you'll find out why some of the most world-changing discoveries come from people with no personal stake—and how AI, chocolate, and mountain biking fit into the life of a master connector.Get the inside edge on biotech breakthroughs, community building, and some great behind-the-scenes laughs in this episode of Thrive Loud!00:02 - Show introduction and welcome00:25 - Hilarious technical misadventure: the unplugged cord 02:09 - Robert Christmas's entry into life sciences 03:33 - Overview of the Philadelphia region's biotech significance 04:19 - How the Pennsylvania Biotechnology Center started and grew 05:51 - Types of medical breakthroughs at the center 07:59 - Spotlight: scientists who brought drugs to market 08:34 - Robert Christmas on the Union League, Philly's historic Life Science Affinity Club 10:00 - Launching a new Life Science podcast 11:28 - The power and reach of Philly's innovation ecosystem 12:37 - How the work personally impacts Robert Christmas 14:32 - Where to find, support, and connect with these organizations 17:02 - Fun speed round: movies, food, activities, and more 19:52 - AI, workflow automation, and the next generation of collaboration 22:15 - Collaborating with Jeff Gibbert and future innovation 22:51 - Closing thoughts and gratitude from Lou Diamond

Did you know that over 75% of silent films have disappeared? The culprit: highly flammable film! We open this episode of Tiny Matters with a poker bet, a decades long grudge, and a garage full of film before we hop into the rise of nitrate (nitrocellulose) film and how it shaped film history. We chat with Robert Shanebrook, who literally wrote the book on Kodak film, and with collection manager Deborah Stoiber at the George Eastman Museum, the world's oldest photography museum and one of the oldest film archives. We talk about the science of preserving and conserving the nitrate films that have survived, and why it's so important for keeping cultural memories alive. Did you know that ‘George Eastman, Kodak, and the Birth of Consumer Photography' is a National Historic Chemical Landmark? Read more about it here. Check out Wow if True here or wherever you listen to podcasts!We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In December 1996, a 37 year old pharmaceutical executive sat in a Borders bookstore reading medical textbooks on the floor, trying to understand a disease she had never heard of. Multiple myeloma carried a three year prognosis. Her daughter was 18 months old. Her father had just died of cancer. Within weeks, she pushed her doctors to say the quiet part clearly. This would likely end her life before her child entered kindergarten.Kathy Giusti refused to accept passive survival. She built a plan while the system offered fragments. She interviewed oncologists and fertility specialists at the same time. She pursued IVF to have a second child while preparing for treatment. She stayed employed to keep insurance coverage. Every decision carried financial, medical, and emotional risk.That same urgency exposed a deeper failure. Cancer research moved slowly. Academic centers guarded data. Clinical trials lacked coordination. Patients entered a system that demanded compliance without providing clarity. Giusti responded by building the Multiple Myeloma Research Foundation, not as a support group, but as an operating engine to accelerate drug development, fund research, and force collaboration across institutions.This episode tracks the tension between individual agency and systemic failure. Giusti describes how patients navigate diagnosis, insurance barriers, and fragmented care in real time. She explains how data, genomics, and clinical trials reshape cancer treatment while still leaving patients responsible for decisions they are not trained to make. She addresses disparities in access, the limits of early detection, and the reality that progress in oncology often depends on speed, funding, and alignment of incentives.The conversation moves between lived experience and structural critique. It names the cost of delay, the burden placed on patients to act as their own advocate, and the tradeoffs required to push a system forward that still protects itself first.⸻RELATED LINKSKathy GiustiMultiple Myeloma Research FoundationFatal to FearlessAmerican Society of Hematology⸻FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Catherine is a Global Market Intelligence Manager in the Life Sciences industry. In this episode we talk about:  How to be the person job descriptions are written for.  Creating new opportunities within your organisation in a declining jobs market.  How to be CEO of your own mind and be free of old patterns of thinking.  Connect with Catherine  https://www.linkedin.com/in/catherine-mcdonnell-5a9ab722/  Kickstart your Intentional Careers Journey  Take the Career Accelerator Scorecard: https://scorecard.intentional-careers.com/strategy  Register for a free Intentional Careers workshop: https://intentional-careers.com/workshop/  Read The Book 'Intentional Careers for STEM Women': https://amzn.eu/d/bL9r8h0    Connect with Hannah  https://hannahnikeroberts.com/  www.linkedin.com/in/hannahrobertscoaching  www.facebook.com/drhannahroberts  X (Twitter) @HannahNikeR  Instagram @drhannahroberts  TikTok @drhannahroberts  YouTube @drhannahroberts 

Updated re-release. A year ago we left one question unresolved. Where do foundational AI models end and where do the applications begin? Nick Tippmann returns in a fresh epilogue.  A year on, the tension has only sharpened. Specificity is the differentiator when inches matter. Nick Tippmann, founding partner of TipTop VC, explains how vertical AI is rewriting the software industry by going deeper instead of wider. From the transition beyond SaaS to the gray zone between foundational models and high-stakes applications, we get into how vertical AI can transform laggard industries and why Austin might lead the race.The Agenda00:00 Defining vertical AI05:07 Where general AI fails09:36 Vertical AI software, not just chatbots16:44 Pricing logic after the seat model24:04 Underwriting at pre-seed and seed 27:20 Capital intensity and seed-strapping36:48 TAM analysis and the Frontiers Market example41:46 OpenAI's Instacart hire and the gray zone45:55 Austin as a vertical AI hub58:21 Epilogue: Where the models end and applications beginGuest Links and BiosNick Tippmann, TipTop VCNick Tippmann is the Founder and Managing Partner of TipTop Ventures, an early-stage venture fund focused on Vertical AI. Before becoming an investor, Nick spent nearly a decade as a founding team member and CMO at Greenlight Guru, where he helped scale the company from zero to category leader with more than 250 employees, tens of millions in ARR, and a nine-figure investment from JMI Equity.An operator turned investor, Nick now partners with founders building industry-specific AI and software businesses, bringing hands-on experience in go-to-market strategy, scaling, community building, fundraising, and company development. He has also been an active angel investor since 2021, with more than 100 startup investments. -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

Healthcare technology should quietly remove friction and reduce burden so clinicians can focus on what matters most: caring for patients in a more human way. In this episode, Lisa Gulker, Chief Nursing Officer at Oracle Health and Life Sciences, discusses how Oracle is rethinking healthcare technology by building AI directly into the foundation of its systems rather than layering it on as an afterthought. She explains how this approach can help clinicians spend less time in the chart, reduce workflow fragmentation, and make technology feel more seamless in the care experience. Lisa also shares how Oracle is applying these capabilities across providers, life sciences, and payers, creating opportunities to accelerate research, improve clinical trial matching, streamline prior authorization, and reduce administrative burden across the ecosystem. Throughout the conversation, she brings a nurse leader's perspective to a central question in healthcare innovation: how do we use technology to make care feel more human, not less? Tune in and learn how embedded AI could reshape the healthcare experience for clinicians, staff, researchers, payers, and patients alike! Resources: Connect with and follow Lisa Gulker on LinkedIn. Follow Oracle Health on LinkedIn and visit their website!

In this episode of Tiny Show and Tell Us, a listener asks: Could we still be carrying air from our very first breath? Deboki unpack's residual lung volume, gas exchange, and a forensic technique used to determine whether or not someone drowned. Then, the conversation turns to women's health and bleeding disorders after a listener shares their experience living with Von Willebrand disease — the most common bleeding disorder. Sam explores what the condition is, how it was discovered, why it disproportionately affects women, and how normalizing heavy, painful periods is not just frustrating but has serious medical consequences.Check out Pale Blue Pod here or wherever you get podcasts!We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In some of our previous episodes, we've explored the interesting paths that  Wolf Greenfield attorneys have taken as they eventually made their way to IP law. One thing that separates Wolf Greenfield from other firms is the depth of real-world experience many of its attorneys possess. In fact, over half of the professionals at Wolf Greenfield worked in science and technology industries prior to entering law.Kevin MacDonald, a Shareholder in Wolf Greenfield's Biotechnology practice, is an ideal example. After earning a degree in biology at Boston College, Kevin went to England to get his Master's in Molecular Biology and then back to North America for his PhD at McGill University's Institute of Parasitology in Montreal. Before his graduate studies and eventually going to law school, Kevin worked as a Life Science and Healthcare Industry Analyst at the British Consulate-General in Boston.In this episode of IP Talk with Wolf Greenfield,  Kevin discusses his path from the world of science to IP law and his current work assisting clients with IP strategy, portfolio management, and patent prosecution and counseling.Here are a few highlights from the conversation:01:18 - Kevin's background in biology02:33 - How Kevin became interested in parasitology03:10 - Serving as an analyst at the British Consulate-General04:21 - Making the switch to law05:38 - The challenges of transitioning from science to a legal career06:21 - Kevin's current practice at Wolf Greenfield07:20 - Some of the most exciting things happening in biopharma today08:18 - Kevin's efforts as a board member of the British American Business Council of New England###

This episode,  Heather and Matthew welcome attorney John Erwin, the newest addition to Maynard Nexsen's Health Care and Life Sciences team, to discuss the landscape of mergers and acquisitions in the life sciences industry. John shares insight from his decades of experience in complex healthcare and life sciences transactions, including how data considerations and emerging technologies are shaping deal activity. We also discuss regions like North Carolina's Research Triangle that continue to attract investment. Tune in for a look at how transactional strategy is adapting and what may lie ahead for life sciences over the next year!

At 19, Shlomit woke up unable to speak. The right side of her body went numb. An emergency room sent her home and called it stress. That moment did not end in a diagnosis that changed policy or triggered reform. It sent her into a decade long pursuit of understanding how the brain fails language and how the healthcare system fails patients who cannot advocate for themselves.Shlomit trained as a speech language pathologist and spent years inside acute care hospitals and ICUs, performing endoscopies and treating patients with brain injury, stroke, and dysphagia. She watched medical teams rotate in and out, deliver dense updates, and leave families nodding without comprehension. She stayed behind and translated. Every day, patients told her she was the only one who explained what was happening. That gap is not an accident. Hospital systems optimize for throughput, not understanding. Patients move through beds based on cost, not readiness. Discharge planning becomes a financial decision wrapped in clinical language. A stay under 48 hours can shift the insurance burden dramatically, leaving patients exposed to higher out of pocket costs. Shlomit left the system and built Patient Path NYC, a private patient advocacy service. She now spends 15 to 20 hours a week per client reading charts, coordinating care teams, and translating medical decisions into plain language. Her work sits in the uncomfortable space between healthcare policy and lived experience. Families pay out of pocket to understand their own care. Hospitals benefit from the clarity she provides while maintaining the same structural incentives that created the confusion.This conversation tracks the human cost of fragmented care, the economics behind discharge decisions, and the quiet reality that patients who cannot communicate clearly often lose control of their own outcomes.RELATED LINKSShlomit LibertyShlomit Liberty on LinkedInPatient Path NYCBoard Certified Patient AdvocateFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Your AI plan can't outrun your data. Adam Marko, life science field CTO at Hammerspace, joins the podcast to unpack the problem almost every biotech, pharma, and biomedical research group runs into: unstructured data that are siloed, fragmented, and scattered across storage systems, sites, and clouds. With host Jessica StLouis, they talk through what “data orchestration” means when building an AI-ready data foundation, infrastructure constraints and the tiered storage patterns that help teams keep AI and HPC workloads moving, and why life sciences are in a uniquely tough spot. Plus, Marko shares a preview of his presentation at Bio-IT World Conference & Expo in Boston.  If you care about faster discovery, smoother AI workflows, and fewer manual file moves, subscribe, share this with a colleague, and rate or review so more researchers can find the conversation. Links from this episode:  From Data Chaos to Discovery: Building the Data Foundation for AI-Ready Scientific Research Bio-IT World Conference & Expo Bio-IT World BioTeam Hammerspace Bio-IT World's Trends from the Trenches podcast delivers your insider's look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. 

Live from BPI West

In 2020, developmental biologist Dr. Crystal Rogers drove the country roads outside Davis, California crying between grant rejections, wondering whether she was about to lose her lab, her career, and the scientific future she had spent years building. She had already done what academia tells young scientists to do. She earned the credentials. She landed a faculty position at UC Davis. She built a lab. Then the real test began.On this episode of Standard Deviation, Dr. Oliver Bogler examines the unspoken rules that determine which scientists survive academic research and which quietly disappear from it. The conversation follows Crystal Rogers and cancer biologist Dr. Michelle Mendoza as they collide with the “Hidden Curriculum” of biomedical science: the unwritten rhetoric, institutional signaling, and grant writing strategies that often decide who receives funding, tenure, and long term stability.Michelle Mendoza entered a tenure track position at the Huntsman Cancer Institute while raising 3 children, navigating a divorce, and trying to secure major NIH funding during COVID. What looked like objective scientific review turned out to depend heavily on persuasion, presentation, and insider fluency. Established researchers could promise massive research agendas based on reputation alone. Junior investigators faced a completely different standard.Oliver traces how the Life Science Editors Foundation and its JEDI program intervened by pairing scientists with former editors from journals including Cell and Nature. The work had little to do with commas or grammar. Editors challenged logic, structure, and scientific framing before grant reviewers could destroy an application in public.Both researchers eventually secured career defining grants. One realized she would keep her job and not have to move her family. The other celebrated by ordering a personalized “DEV BIO” license plate and driving through Davis blasting nineties hip hop and Beyoncé.The episode exposes how biomedical research funding rewards institutional fluency as much as scientific talent, and how hidden systems inside academic medicine continue shaping who gets to stay in science long enough to make discoveries.RELATED LINKSDr. Crystal Rogers LinkedInDr. Crystal Rogers Faculty PageDr. Crystal Rogers LabDr. Michelle Mendoza LinkedInDr. Michelle Mendoza Faculty PageHuntsman Cancer Institute Mendoza LabLife Science Editors FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of The Global Marketing Show, international project leader Franziska Höhne shares a practical, real-world framework for managing global teams where precision, compliance, and cross-border alignment are non-negotiable. Drawing from nearly 20 years of experience leading complex international projects, Höhne makes one thing clear: you're not managing functions, you're aligning humans across cultures. In regulated environments, the ability to build trust across geographies becomes a core operational capability. She emphasizes the importance of humanizing virtual teams, ensuring that colleagues don't just interact as roles on a screen, but as real people with context, constraints, and different ways of working. A major theme in the conversation is how language creates hidden risk, even when everyone speaks English. Subtle phrases like “let's revisit the timeline” can signal urgency in one culture and optional follow-up in another. In high-stakes environments like clinical development, regulatory submissions, or global product rollouts, these small misunderstandings can have outsized consequences.  To navigate this complexity, she introduces a simple but powerful framework built on three pillars: Human connection: Build trust by seeing people, not just roles Language precision: Be intentional with wording, tone, and expectations Operational structure: Standardize how teams communicate, document, and respond across regions This framework becomes especially critical when managing teams across multiple time zones. Höhne shares a practical solution: rotate meeting times so no single region consistently absorbs the burden of off-hours collaboration. Combined with clearly defined communication protocols and documentation standards, this creates a more equitable and effective global operating model. The episode also reinforces a key insight for regulated industries: while English may be the working language internally, translation and localization remain essential for external-facing materials. Precision isn't optional when compliance and clarity are on the line. For leaders in Life Sciences, medical devices, manufacturing, CPG brands, and other regulated sectors, the takeaway is direct: global success depends on how well your teams communicate across borders, not just what they build.  Check out The Global Marketing Show Blog.

Chase Dorsey is a Sales Engineer at Inductive Automation. Since 2020 Chase has been helping manufacturers improve their operations with Ignition by Inductive Automation. Ignition brings affordable Digital Transformation to industrial operations. With just one server license, manufacturers can connect all their devices and collect more data. The Industry 4.0 Podcast with Grantek delivers a look into the world of manufacturing, with a focus on stories and trends that lead to better solutions.   Our guests will share tips and outcomes that will help improve your productivity. You will hear from leading providers of Industrial Control System hardware and software, Grantek experts and leaders at best-in-class industry associations that serve the Data Centers, Life Sciences, CPG and Food & Beverage industries.

In the early 1930s, a “new and improved” eyelash dye called Lash Lure blinded more than a dozen women, ultimately forcing the FDA to pass new regulations on cosmetics. Nearly a century later, beauty remains far safer than it was in the past, but you could argue that beauty marketing has become far more insidious, with vague language and chemophobic claims to push consumers toward products. In this episode, we chat with cosmetic chemist and science communicator Michelle Wong to unpack the booming “clean beauty” industry, including a conversation about parabens and fragrances and how chemophobia (a fear of chemicals) early in life can become a gateway to broader anti-science thinking, including anti-vax. You can follow Michelle at @LabMuffinBeautyScience on Instagram, TikTok, and YouTube where she makes longer explainer videos. Check out Wow if True here or wherever you listen to podcasts!We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Whether advancements in crops or livestock, upgrading mechanization or efficient use of resources, research carried out by universities has gone a long way to the abundance in agriculture that benefits us all.  It's a top priority for the University of Idaho, one of the top ag schools in the nation. Leslie Edgar, Dean of the University's College of Agricultural and Life Sciences, recently visited Redox Headquarters to strengthen our partnership. "Theory is amazing, but making sure that we can actually apply it so it works for producers is really important," Edgar said. "That's the blessing of being at a land-grant university that we get to do that. The value of us partnering with companies like Redox is that you have the innovation, and that we have the scientists and the students that can work with you and then partner at a really high level."

In this special rerun episode of The Poultry Nutrition Blackbelt Podcast, Dr. Birger Svihus from the Norwegian University of Life Sciences breaks down how particle size affects broiler feeding behavior. He shares insights into how birds select feed particles, their preferences for fines, and the implications for feed formulation. Find out how a closer look at pecking patterns could change the way we think about poultry nutrition. Listen now on all major platforms!"The bird is pecking more than once per second. So it's an extremely rapid rate of pecking."Meet the guest: Dr. Birger Svihus earned his Ph.D. in Poultry Nutrition from the Agricultural University of Norway, where he currently serves as a professor at the Norwegian University of Life Sciences. His work focuses on cereal fiber, starch, feed structure, and digestive function in poultry. He's published extensively and leads nutrition research across Europe. Learn more about his approach on The Poultry Nutrition Blackbelt Podcast. Listen now, featuring Dr. Birger Svihus on all major platforms.Liked this one? Don't stop now — Here's what we think you'll love!What you'll learn:(00:00) Highlight(01:18) Introduction(02:29) Particle size impact(03:38) Feeding behavior science(05:58) Beak capacity limits(08:33) Preference for fines(09:42) Size vs. nutrient delivery(11:31) Closing thoughtsThe Poultry Nutrition Blackbelt Podcast is trusted and supported by innovative companies like:* Fortiva* Kemin- Poultry Science Association- Anitox- DietForge

In 2008, Katy Talento walked away from Capitol Hill and into a Catholic convent. Within a year, she walked out. Within another decade, she sat inside the White House shaping health policy. Somewhere in between, she got labeled “infertile” after a single cycle of testing and spent years believing it.That label stuck. The pain that came before it never got investigated. Doctors offered birth control and moved on. No one asked why her body was struggling. No one followed the thread.Talento built her career inside the very systems she now critiques. She worked on federal health policy, global disease programs, and later advised the Trump administration on healthcare reform. She helped advance price transparency rules in a system where hospitals can still list 457 different prices for the same service.Then she left.Now she builds employer health plans that bypass insurers, PBMs, and traditional networks. Her approach replaces insurance contracts with direct payment, nurse navigators, and cost sharing models that promise simplicity but raise hard questions about risk and protection.This conversation sits in that tension.Talento describes a healthcare system shaped by layered incentives, where insurers, hospitals, and intermediaries profit from complexity. She argues that employers hold the leverage to disrupt it. The host pushes on what happens when patients fall outside those structures, when contracts disappear, and when community based models fail.The episode moves through infertility, misdiagnosis, insurance design, and the mechanics of employer sponsored care. It tracks how policy decisions made in Washington ripple into exam rooms, billing departments, and family lives.It also confronts a harder truth.Even insiders who understand the system can still get caught in it.RELATED LINKSAllBetter HealthKaty TalentoThem Before UsAn Arm and a LegRelentless Health ValueFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Hosts Heather and Lauren are joined by Leslie Isenhour, Dean of Biotechnologies and North Carolina BioNetwork Capstone Center at Wake Tech Community College. With the growing demand for life sciences talent in North Carolina, Dean Isenhour shares how Wake Take is preparing the community through customized training programs, apprenticeships, and early exposure at the high school level. We discuss what draws major companies to the region and how community colleges partner with industry to close skill gaps, as well as the role of workforce development in supporting continued growth in biopharmaceutical manufacturing. Tune in to hear how education, infrastructure, and community investment come together to build a strong and sustainable talent pipeline in North Carolina!

Have you checked out ACS' new podcast Chain Reaction? Today we're bringing Tiny Matters listeners one of our favorite episodes! Chemistry doesn't just shape conflict — conflict shapes chemistry. And at no time in history is that more apparent than during the two world wars. Historian Alison McManus recounts how the race to weaponize toxic gases like chlorine and mustard gas transformed chemists into key military players, spurred industrial growth, and ignited an international arms race during WWI. However, some battles of the world wars weren't waged against an opposing army, but against diseases that soldiers caught while in combat. Journalist Karen Masterson reveals how WWII triggered a massive scientific mobilization — a secret, high‑stakes search for synthetic quinine and antimalarial drugs that would ultimately help seed the modern pharmaceutical industry. Packed with espionage, innovation, and ethical dilemmas, this episode uncovers how war accelerated chemistry in ways that still shape science today.Available wherever you get podcasts! Transcripts and episode sources at acs.org/chainreactionSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This talk was recorded live at Vision Weekend USA, held December 5–7, 2025 in the Bay Area. Vision Weekends are our flagship conference series, bringing together leading scientists, entrepreneurs, funders, and policymakers to explore frontier science and technology and to imagine paths toward flourishing futures. Hosted on Acast. See acast.com/privacy for more information.

In this episode of Tiny Show and Tell Us, we welcome our first‑ever guest, podcast producer and dinosaur enthusiast Steven Ray Morris. Together, we dive into three wildly different stories. First, we explore a major advancement in HIV prevention: a newly approved twice‑yearly injectable drug called Lenacapavir. We chat about how it works, why it's a huge shift from daily pills or monthly shots, and the challenges around global access. Next, Steven takes us deep into the (mostly chilly) past — to Antarctic dinosaurs! What scientists are learning about these dinos is shifting what we think we know about where, and how, dinosaurs lived. Finally, Deboki breaks down the science behind blood flow restriction therapy, a rehabilitation technique that helps injured muscles rebuild strength using lighter loads. As always, Tiny Matters is not giving anything that could be interpreted as medical advice! Deboki also reveals she's into weightlifting. So yeah, don't mess with Deboki! You can find Steven and See Jurassic Right lots of places! Including Instagram, Apple Podcasts, Patreon and Etsy.Check out Spirits here or wherever you get podcasts!We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

As many life sciences companies prepare for strategic exits, existing collaboration partners can make or break the deal. Join Troutman Pepper Locke Partners Mindy Rudolph and Mandy Hassan as they discuss how targets can navigate M&A transactions when key assets are tied up in complex licensing and collaboration arrangements. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In a wooded campground cabin in the early 2000s, 19 year old Ben Unger stood in the doorway and watched 20 naked men form a circle around a crying teenager. A counselor held up two tangerines and shouted, “These are your balls.” The exercise claimed to cure same sex attraction by forcing young men to “reclaim” their masculinity from overbearing mothers. Phones had been confiscated. Parents had paid thousands of dollars. Religion supplied the script. Pseudoscience supplied the props.Ben had grown up in an Orthodox Jewish community in Brooklyn and later studied in Israel to become a rabbi. When he admitted he felt attracted to men, rabbis told him to eat 7 figs a day, immerse in a ritual bath 5 times daily, or marry a woman and trust that “if there's friction, it works.” At 19, he entered conversion therapy through an organization called Jews Offering New Alternatives to Homosexuality, known as JONAH. He left with depression, religious trauma, and 6 months of silence toward the mother he had been taught to blame.Years later, represented by the Southern Poverty Law Center, Ben helped sue JONAH for consumer fraud in a landmark New Jersey case. The argument centered on evidence, not theology. Sexual orientation cannot be changed. The jury deliberated for 3 hours and ruled against the organization. The verdict helped reshape how states regulate conversion therapy and protect minors from psychological harm disguised as treatment.Today, Ben runs Buff Personal Training in New York City, a gym built on autonomy, mental health, and self respect. His story traces the arc from institutional control to self authorship. The conversation examines religion, LGBTQ rights, conversion therapy, consumer protection law, and the lasting cost of being told your identity is a disorder.RELATED LINKSBen Unger on LinkedInBen Unger on InstagramBUF Personal TrainingSouthern Poverty Law CenterJONAHFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

As the 2026 midterm elections approach, healthcare leaders are asking whether this is just another policy cycle or a more pivotal moment in an increasingly complex and fragmented landscape. In this episode of PwC's Next in Health, Glenn Hunzinger speaks with Kelly Griffin and Philip Sclafani about how shifting policy dynamics, persistent cost pressures, and rapid industry transformation are reshaping strategy across the healthcare ecosystem. Discussion highlights:Why the 2026 midterms are less about sweeping reform and more about signaling the direction of the operating environmentHow affordability, transparency, and increased state-level action are shaping policy and driving industry changeWhy healthcare costs continue to rise and why traditional levers may not be enough to bend the cost curveHow pharma, payers, and providers are adapting business models amid regulatory pressure and evolving market dynamicsThe growing role of AI, partnerships, and ecosystem convergence in accelerating transformationWhat healthcare leaders should prioritize, from policy intelligence and scenario planning to operating effectively in a more fragmented environment  Speakers: Glenn Hunzinger, US Health Industries Leader, PwC Kelly Griffin, Director, Health Policy and Intelligence Institute, PwC Philip Sclafani, Principal, Pharmaceutical and Life Sciences, PwCFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

In this episode, Tom Fox welcomes Edye Edens about launching her Life Sciences Law Group (“Eedee Law”) after years of contracting in life sciences compliance across multiple firms. Edye explains she founded the firm to better align her practice with supporting clinical trial sites, vendors, and academia, which often lack the budgets and in-house legal resources of sponsors and CROs. She describes a multidisciplinary team model that includes non-attorney quality, TMF, regulatory, and inspection-readiness professionals with deep study-operations experience, enabling rapid, practical support at different price points, including fractional engagements and urgent FDA inspection support. Edye outlines four core client segments: independent sites/site networks, academic medical centers' research compliance functions, NCI-designated cancer centers, and vendors entering clinical trials who need guidance on Part 11, HIPAA, QMS, and vendor qualification. She discusses growing AI-related client needs, emphasizing evolving regulatory expectations and “compliance at the speed of business,” and shares how to connect via website, LinkedIn, and email. Key highlights: Building A Different Firm Indy Roots National Reach Lessons From Academic Medicine AI Vendors And Regulation Resources: Edye Edens on LinkedIn Eedee Law Tom Fox Instagram Facebook YouTube Twitter LinkedIn For more information on the use of AI in compliance programs, Tom Fox's new book, Upping Your Game, is available. You can purchase a copy of the book on Amazon.com. To learn about the intersection of Sherlock Holmes and the modern compliance professional, check out Tom's latest book, The Game is Afoot-What Sherlock Holmes Teaches About Risk, Ethics and Investigations on Amazon.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Disruption/Interruption, host KJ sits down with Ome Ogbru, PharmD, CEO and founder of AINGENS, to tackle a decades-old problem hiding in plain sight: life sciences runs on groundbreaking science, but is buried in broken processes. After 20+ years as a clinician, professor, and pharmaceutical executive, Ome reached a breaking point, and instead of finding a new job, he built a new company. He shares how generative AI, used responsibly and strategically, can finally give researchers their time back, cut through misinformation, and help the right information reach the right people faster. Four Key Takeaways: The scientific content workflow is fundamentally broken [4:15] -- Research teams are so resource-strapped that PhDs spend their time managing IT systems instead of doing science. Procuring a software solution could take one to two years and often didn't even solve the right problem. Generative AI isn't the magic wand, it's how you use it [20:01] -- When Ome first tested ChatGPT on biotech content and got poor results, he had a revelation: the tool wasn't the problem. The problem was not knowing how to use it. Pairing AI with deep domain expertise and proper workflows is where the real power lies. The human expert must remain in the driver's seat [32:30] -- AINGENS' platform (MACG) is built so the professional is in control. The AI handles the time-consuming, mundane tasks like literature search, drafting, and formatting, while the expert applies regulatory knowledge, judgment, and guardrails. Misinformation in life sciences is a public health problem [35:49] -- Misinformation travels faster than accurate data. Ome's vision is for generative AI to help industry proactively get accurate, personalized scientific information to the people who need it, patients, clinicians, and researchers alike, before the noise wins. Quote of the Show (35:41):"Misinformation flies faster than correct information." -- Ome Ogbru Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Ome Ogbru:LinkedIn: https://www.linkedin.com/in/ome-ogbru-pharmd/Company Website: http://www.aingens.com How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

In this episode, we dive into the murky, high‑stakes world of deep-sea mining — the practice of extracting valuable metals from the ocean floor. Deep-sea mining has been “just around the corner” for decades. So what's the holdup? With the help of deep-sea ecologist Andrew Thaler and oceanography researcher Michael Dowd, we discuss what makes the deep ocean such a challenging place to operate, and unpack why polymetallic nodules have drawn so much interest, and why removing them could permanently alter ecosystems we barely understand. The episode also looks ahead, asking whether deep-sea mining is even necessary and what it could mean not just for Earth's oceans, but for future resource extraction in places like Antarctica and the Moon. It's a story about science, but also Victorian research ships, CIA cover stories, “shark potatoes,” and vast, untouched ecosystems. Check out Dreaming Against the Machine here or wherever you listen to podcasts.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Recorded at the SCbio Annual Conference, hosts Heather and Lauren welcome John Balchunas, Workforce Director at the National Institute for Innovation in Manufacturing Biopharmaceuticals, known as NIIMBL. John shares insight into how the life sciences industry is approaching workforce and talent development at a national level. The conversation explores challenges facing the biopharmaceutical manufacturing workforce, the growing influence of automation and AI, and why skills based hiring and regional cooperation will play an important role in building a sustainable talent pipeline. Tune in for a look at how organizations are working to future-proof the workforce behind advanced manufacturing and life sciences innovation!

This was not the episode we planned. Will Johnson, founder and CEO of Gyde, and Alex Cohen, founder and CEO of Hello Patient, came on to talk about innovation in the business of health. Instead it became our off the record conversations, but behind the microphone. An unfiltered field report on what it actually feels like to build a startup in Austin right now. The talent math, hunting for mid-size office space, the venture culture, Austin vs Miami, the press gap, and the political friction. All of it from two founders who chose this city, are hiring here, and are naming what needs to change because they want it to work. Agenda0:00 Why Alex and Will chose Austin5:17 The engineering talent gap 14:10 Who gets hired and the conference hustle 20:58 Miami, Palantir, and competing for wins 26:02 What SF's venture culture has that Austin is still building32:58 Operator density problem and the office gap 41:05 Why selling to Main Street works better from Austin 50:16 More storytellers needed59:16 SXSW's decline 1:05:18 King of Austin for a dayGuest Links and BiosAlex Cohen: X/Twitter, LinkedIn, Hello PatientWill Johnson: X/Twitter, LinkedIn, Gyde -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

Drew Flugstad-Clarke never planned to work in brain cancer. She planned to play Division I soccer at Georgetown. She planned to paint. She even tried investment banking, answering emails at 4am in a cubicle that never slept. Then in June 2022 her father, Jim, was diagnosed with glioblastoma at 57. He died 1 day shy of 7 months later, just before his 58th birthday. His symptoms began with emotion, not seizures. A steady HR executive suddenly cried. His golf game slipped. By the time he entered the hospital for a scan, he did not leave without surgery. A subway poster for a 5K became a lifeline. Drew showed up. She found a community. She later joined the American Brain Tumor Association as Community Manager for the Eastern Region. This conversation walks through anticipatory grief, caregiving in real time, strategic numbness, and what it costs to curate hope when the median survival clock is already ticking.RELATED LINKSDrew Clark Flukestad on LinkedInTopor StudiosAmerican Brain Tumor AssociationGeorgetown University Women's SoccerFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Innovation in life sciences is accelerating; the way companies manage their customer relationships is not. That gap — between the speed of science and the pace of commercial relationship-building — is the uncomfortable starting point for this Resonance Test conversation with Dinesh Salvi, Former Vice President, Head of Digital & IT Customer Engagement Platforms at Bristol Myers Squibb and Markus Hinderberger, Global Head of Commercial Advisory at EPAM. These two practitioners have spent considerable time thinking about what modern engagement requires. Hinderberger names the core problem plainly: Too many organizations are still running "a CRM that behaves like a glorified call-recording tool." The system exists, the fields get filled in and the boxes get checked, but the intelligence never compounds and the experience never improves. Salvi agrees and identifies the real obstacle. (Spoiler: It's not the technology.) "The biggest difference is adoption and use," he says. Features don't matter if the people who use the tool don't trust it. For that to happen, the CRM has to earn its place — becoming something closer to a "companion" that supports work… and doesn't add friction to it. Both men say volume is no longer the metric that matters. Access to customers today is selective. "The doors are open," says Hinderberger, "but they're only open to a few" — the companies that show up with something genuinely useful every time. That raises the stakes on each and every interaction, and it changes what good preparation looks like across the commercial organization. Meeting that bar requires more than a motivated sales rep. It requires personalization and orchestration across channels, and it can't live inside a single function. Salvi and Hinderberger talk through what it means to create a genuine "red thread" connecting every touchpoint: the reimbursement specialist, the nurse educator, the sales representative, the medical science liaison, the call-center staffer. When those people operate as disconnected nodes, the customer experience feels episodic. When they share context, it feels consistent — and that consistency is what builds the kind of relationship that survives a crowded market. Of course, modernization has to survive reality, too. The conversation doesn't shy away from the practical constraints that most of the health ecosystem is working with: limited budgets, legacy platforms, and what Salvi describes as the "patchwork" that defines most commercial tech stacks. So should life sciences orgs pursue "big T or little T" transformation? And how is momentum kept alive while working toward something more ambitious? Hinderberger's approach is pragmatic: Define the ideal end state, work backwards from it, and make sure near-term wins are real enough to sustain organizational belief in the project. When it works, the payoff isn't prettier dashboards or cleaner pipeline reports. Salvi argues that a CRM that becomes a true "copilot" can deliver value "tenfold" — finally giving organizations the ability to capture real field data and activate it in an intelligent ecosystem. That's the version of CRM that justifies the investment. That's also the version most life sciences companies haven't built… yet. Host: Jonathan Swersey Engineer: Kyp Pilalas Producer: Gabrielle Semon Executive Producer: Ken Gordon

Invest Like the Best: Read the notes at at podcastnotes.org. Don't forget to subscribe for free to our newsletter, the top 10 ideas of the week, every Monday --------- My guest today is Alex Karnal. Alex is the co-founder and managing partner of Braidwell, a life sciences investment firm he built after spending 15 years at Deerfield Management. The frame we use throughout the episode is the health stack. Alex talks about how most of the diseases that will claim most of our lives are already addressable with medicines that exist today. We work through the five layers of what a defensive health strategy looks like, why GLP-1 medicines represent the first commercial proof that people are ready to be proactive about their health, and why PCSK9 inhibitors may ultimately be the more important drug class even though they get far less attention. We also get into the science and business of drug discovery itself — why most of the published literature that AI companies are training on cannot be replicated, what it would mean to have a truly agentic scientific lab running 24 hours a day, and why Alex believes we are now on a deterministic curve toward scientific superintelligence in biology. For the full show notes, transcript, and links to mentioned content, check out the episode page ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠.  ----- Become a Colossus member to get our quarterly print magazine and private audio experience, including exclusive profiles and early access to select episodes. Subscribe at ⁠colossus.com/subscribe⁠. ----- ⁠Ramp's⁠ mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠ramp.com/invest⁠⁠ to sign up for free and get a $250 welcome bonus. ----- Trusted by thousands of businesses, ⁠Vanta⁠ continuously monitors your security posture and streamlines audits so you can win enterprise deals and build customer trust without the traditional overhead. Visit ⁠vanta.com/invest⁠.  ----- ⁠WorkOS⁠ is a developer platform that enables SaaS companies to quickly add enterprise features to their applications. Visit⁠⁠ ⁠WorkOS.com⁠⁠⁠ to transform your application into an enterprise-ready solution in minutes, not months. ----- ⁠Rogo⁠ is the AI platform for finance. They're building agents for Wall Street that are trained to understand how bankers and investors actually do work: from diligence and modeling, to turning analysis into deliverables. To learn more, visit rogo.ai/invest. ----- ⁠Ridgeline⁠ has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. Visit⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ridgelineapps.com⁠. ----- Editing and post-production work for this episode was provided by The Podcast Consultant (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thepodcastconsultant.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). Timestamps: (00:00:00) Welcome to Invest Like the Best (00:02:29) Intro: Alex Karnal (00:03:15) State of the Union: GLP1s and Life Sciences (00:07:01) The Health Stack Framework (00:12:49) Breaking Down the 5 Defensive Layers (00:21:18) GLP-1: What's Driving the Inflection (00:28:28) Diet vs. Drugs: Is Food Enough? (00:31:15) Barriers to Access: Complexity, Cost & Compliance (00:35:04) PCSK9: The Closest Thing to a Free Lunch (00:44:10) Alzheimer's & Neurodegenerative Disease (00:46:59) Cancer: Early Detection & New Treatments (00:54:49) Body Imaging & Diagnostic Trade-offs (00:56:31) How Drugs Are Discovered (01:02:39) AI in Drug Discovery (01:10:57) The Automated Lab of the Future (01:13:05) Peptides & Citizen Pharmacology (01:16:45) Alex's Background (01:28:25) Braidwell's Investment Approach (01:30:39) The Kindest Thing

ICON has been telling the same story since 2018. Humanity has a construction problem that solving for regulations and supply-demand incentives alone won't fix. We need fundamentally new ways to build. Jason Ballard, ICON's founder and CEO, and Will Hurd, the former CIA officer, congressman, and OpenAI board member who just joined as President of ICON Prime, came on to lay out what happens when a non-consensus thesis held for eight years starts to materialize in the real world. The conversation cuts across the full stack, housing, AI, robotics, labor, reindustrialization, and space. The through-line is Ballard's argument that breakthrough technologies are never narrow, that building the technology for a moon base solves the housing and building crisis on Earth. Agenda0:00 What ICON is building and why shelter is broken 6:40 The regulation stack and ICON as a technology company 11:40 Customer shapes, business model, and the innovation stack 17:10 AI, ChatGPT from the inside, and the case for optimism 23:40 The spoons-and-ditches fallacy and Hurd's regulation inversion 30:30 What is ICON Prime and the barracks crisis 36:40 Military construction, Afghanistan, and expeditionary printing 42:40 The moon base, Olympus, and in-situ resource utilization 49:40 Eight years of the same thesis and software's limit 56:40 Austin's talent gravity and the ICON diaspora 1:00:40 The moon in our lifetime 1:04:40  National security, espionage, and Austin as a target 1:08:40 Laser on the moon, 2028 Previous ICON Episode with Evan LoomisGuest Links & BioJason Ballard: X/TwitterWill Hurd: LinkedInICON: Website, ICON Prime, X/Twitter, LinkedIn, YouTubeJason BallardJason Ballard has dedicated his life to working on big problems in service to humanity, most recently and notably as the co-founder and CEO of ICON, the construction technologies company using construction-scale 3D printing to tackle the global housing crisis and prepare to build on other worlds. ICON has been named one of the "Most Innovative Companies in the World" by Fast Company and recently profiled on CBS's 60 MINUTES.  Raising $451 million to date in funding, ICON has delivered communities of resilient 3D-printed homes at high-speed and lower cost in the U.S. and internationally and forged partnerships with world-renowned architects, builders and housing organizations missionally aligned to shift the paradigm of homebuilding. In fall 2022, ICON was awarded $57.2 million from NASA to develop a lunar surface construction system that will target humanity's first-ever construction on another planetary body. In 2019, Ballard was awarded the Austin Under 40 Award in the Technology category. In 2021, Ballard was named to TIME100 Next as one of the emerging leaders shaping the future as well as Newsweek's America's Greatest Disruptors: Visionaries and Innovators Who Are Changing the World. Prior to co-founding ICON, Ballard served as CEO of an eco-friendly home upgrade company that normalized sustainable and healthy approaches to home improvement. Before becoming an entrepreneur, Ballard worked at a homeless shelter, in various roles in sustainable building, and as an environmental consultant for ACRT. Ballard is a GLG Social Impact Fellow and served on the Carbon War Room / Rocky Mountain Institute Energy Think Tank. Ballard hails from East Texas and studied conservation biology at Texas A&M University. He also completed a masters program in Space Resources at Colorado School of Mines in 2022. He enjoys astronomy, ultrarunning, chess, comic books, and outdoor activities when he has free time.  He resides in Austin, TX with his four children.Will HurdThe Honorable Will Hurd is a former CIA officer and congressman whose career spans intelligence, cybersecurity, artificial intelligence policy, and public service. He currently serves as Division President of ICON Prime, a space and defense tech company and will lead ICON Prime's strategy and government partnerships as the company scales its robotic construction technology across the national security enterprise and beyond Earth.  He is also the author of American Reboot: An Idealist Guide to Getting Big Things Done. Hurd brings deep expertise at the intersection of technology, national security, and governance to his board roles and ongoing policy work.Hurd began his career serving overseas in the CIA, where he worked to prevent attacks on the United States and disrupt efforts to smuggle nuclear materials into the country. He later held roles at Crumpton Group and FusionX, helping defend critical infrastructure from cyber threats. In 2014, he was elected to the U.S. House of Representatives, representing Texas's 23rd District, where he served three terms and played a key role in shaping technology and national security policy.Following his time in Congress, Hurd held leadership roles at Allen & Company and CHAOS Industries. He also previously served on the boards of In-Q-Tel and OpenAI.He currently serves on the board of directors for Personal.AI, The Aerospace Corporation, the Council on Foreign Relations, and advisory boards of Palo Alto Networks and the Center for European Policy Analysis.A San Antonio native, Will received a BS in Computer Science from Texas A&M University.  -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

In this episode of Tiny Show and Tell Us, we trace the history of Turner Syndrome — from early clinical observations to the discovery of its chromosomal cause — highlighting how scientists began connecting symptoms to genetics long before DNA was fully understood. Then we follow up on a listener note about lab safety by explaining, at a molecular level, why dimethylmercury and prions are so dangerous to the human body. Ending on something more hopeful, we explore new research showing how engineered yeast could help give honey bees the nutrients they need to thrive. Team bees!Check out American Medieval here or wherever you listen to podcasts!We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

My guest today is Alex Karnal. Alex is the co-founder and managing partner of Braidwell, a life sciences investment firm he built after spending 15 years at Deerfield Management. The frame we use throughout the episode is the health stack. Alex talks about how most of the diseases that will claim most of our lives are already addressable with medicines that exist today. We work through the five layers of what a defensive health strategy looks like, why GLP-1 medicines represent the first commercial proof that people are ready to be proactive about their health, and why PCSK9 inhibitors may ultimately be the more important drug class even though they get far less attention. We also get into the science and business of drug discovery itself — why most of the published literature that AI companies are training on cannot be replicated, what it would mean to have a truly agentic scientific lab running 24 hours a day, and why Alex believes we are now on a deterministic curve toward scientific superintelligence in biology. For the full show notes, transcript, and links to mentioned content, check out the episode page ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠.  ----- Become a Colossus member to get our quarterly print magazine and private audio experience, including exclusive profiles and early access to select episodes. Subscribe at ⁠colossus.com/subscribe⁠. ----- ⁠Ramp's⁠ mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠ramp.com/invest⁠⁠ to sign up for free and get a $250 welcome bonus. ----- Trusted by thousands of businesses, ⁠Vanta⁠ continuously monitors your security posture and streamlines audits so you can win enterprise deals and build customer trust without the traditional overhead. Visit ⁠vanta.com/invest⁠.  ----- ⁠WorkOS⁠ is a developer platform that enables SaaS companies to quickly add enterprise features to their applications. Visit⁠⁠ ⁠WorkOS.com⁠⁠⁠ to transform your application into an enterprise-ready solution in minutes, not months. ----- ⁠Rogo⁠ is the AI platform for finance. They're building agents for Wall Street that are trained to understand how bankers and investors actually do work: from diligence and modeling, to turning analysis into deliverables. To learn more, visit rogo.ai/invest. ----- ⁠Ridgeline⁠ has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. Visit⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ridgelineapps.com⁠. ----- Editing and post-production work for this episode was provided by The Podcast Consultant (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thepodcastconsultant.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). Timestamps: (00:00:00) Welcome to Invest Like the Best (00:02:29) Intro: Alex Karnal (00:03:15) State of the Union: GLP1s and Life Sciences (00:07:01) The Health Stack Framework (00:12:49) Breaking Down the 5 Defensive Layers (00:21:18) GLP-1: What's Driving the Inflection (00:28:28) Diet vs. Drugs: Is Food Enough? (00:31:15) Barriers to Access: Complexity, Cost & Compliance (00:35:04) PCSK9: The Closest Thing to a Free Lunch (00:44:10) Alzheimer's & Neurodegenerative Disease (00:46:59) Cancer: Early Detection & New Treatments (00:54:49) Body Imaging & Diagnostic Trade-offs (00:56:31) How Drugs Are Discovered (01:02:39) AI in Drug Discovery (01:10:57) The Automated Lab of the Future (01:13:05) Peptides & Citizen Pharmacology (01:16:45) Alex's Background (01:28:25) Braidwell's Investment Approach (01:30:39) The Kindest Thing

Janine Durso spent 30 years inside pharmaceutical advertising shaping healthcare narratives before becoming a belief strategist and founder of The Believist. In November 2024, during a routine Zoom coaching session, she felt what she called a sharp, terrible pain in the right side of her head. Within hours she was in surgery for a ruptured brain aneurysm. She does not remember the ambulance, the ICU, or the first weeks that followed. She spent 5 weeks in intensive care, then 10 days relearning how to walk, calculate simple change, and manage basic cognition. Doctors later placed a stent and continue monitoring a second unruptured aneurysm.This episode traces the moment she told her husband something broke in my brain, the 14 days doctors called touch and go, and the slow mental rebuild that followed. It also examines insurance barriers that require 2 direct relatives with aneurysms before screening coverage, and why she now lobbies in Washington for change.RELATED LINKSJanine DursoThe BelievistBrain Aneurysm FoundationWhite Plains HospitalDr. Jared CooperFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Connectivity becomes transformational in healthcare when it helps providers extend their expertise, close access gaps, and support care beyond the hospital walls. In this episode, Robin Goldsmith, Practice Leader for Healthcare and Life Sciences at Verizon Business, shares why connectivity is no longer just infrastructure. It is becoming a strategic foundation for healthcare delivery. Drawing on nearly two decades in the space, Robin explains how the pandemic exposed major gaps in access for patients without reliable devices or networks, and why that moment clarified the role telecommunications can play in healthcare transformation. He discusses the growing pressure on providers to improve patient and clinician experience while managing thin margins, workforce shortages, and rising demand for more distributed care. Robin also highlights how stronger network infrastructure, better partnerships, and new models for rural health, remote monitoring, and even robotic surgery can help health systems expand access and move care closer to patients. Tune in to learn how connectivity is helping healthcare become more responsive, more distributed, and more equitable. Resources: Connect with and follow Robin Goldsmith on LinkedIn! Follow Verizon Business on LinkedIn and explore their website! Listen to the Healthcare of Air by Verizon here.

R&D teams are starting to advance AI capabilities faster than they can translate them into measurable business value, creating mounting friction between scientific progress and operational reality. In this episode, Aziz Nazha, Global Head of AI Innovations Institute at Incyte Pharmaceuticals, examines how culture, talent, infrastructure, and expectation‑setting determine whether AI meaningfully improves drug discovery and development. He highlights the practical shifts required — from redesigning workflows to disciplined upskilling and targeted validation cycles — to ensure AI adoption accelerates cycle times rather than getting stalled by organizational bottlenecks. This episode is sponsored by Deloitte. Learn how brands like Deloitte work with Emerj and other Emerj Media options at go.emerj.com/partner

Our guest for today's podcast is Dr. Gaurav Aggarwal.  Dr. Aggarwal is a Managing Partner at Vivo Capital, a global healthcare specialist with a multi-strategy investment platform covering venture capital, private equity, and public equity strategies. The firm seeks to support the expansion of healthcare access via investments in the industry, and to catalyze innovation and growth via its "Ecosystem Strategy." Dr. Aggarwal and has invested in the life sciences sector for over 25 years including almost 10 years at Vivo Capital at the time of this recording.  Prior to Vivo, Dr. Aggarwal was Chief Business Officer of Ocera Therapeutics, a publicly traded clinical-stage company, prior to which he served as a General Partner at Panorama Capital. He began his career in private equity at JPMorgan Partners. Dr. Aggarwal currently serves on the board of Unicycive Therapeutics and on the boards of several private companies across the medical device, pharmaceutical services and biopharmaceutical sectors. Dr. Aggarwal received his M.D. from Columbia University, College of Physicians & Surgeons and his B.S. in Agricultural Economics from Cornell University. Without further ado, here is our conversation with Gaurav Aggarwal.

In the heart of The Hague, Netherlands, the museum Mauritshuis displays some of the world's most iconic art in its Royal Cabinet of Paintings, including ones from Rembrandt and Vermeer's Girl with a Pearl Earring. But there's another oil painting by Vermeer that is also quite famous, called View of Delft — it's of his hometown, created around 1660.The painting is a cityscape — the only one Vermeer ever painted — a snapshot of the Dutch city of Delft from across the Schie River. In it you see the city's beautiful architecture on full display, including buildings with striking red roofs. Well, at least they used to be red. Today they have a pink-ish hue and if you looked at the painting up close, you'd see that they are covered in white spots. And what may come as a surprise is that they are, in fact, soap. In today's episode of Tiny Matters, we're going to talk about the weird chemistry of soap, what ancient soap was like, and why scientists are finding soap in old oil paintings.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Rebecca Benghiat holds a JD, passed the bar, and skipped corporate law to build mental health systems instead. She now serves as Chief of Staff and Head of Impact at Inner Foundation, where she helps direct capital toward emerging adults ages 18 to 30 and asks a hard question every day: Is this actually working?In this conversation, she dismantles the myth of easy fixes. She explains why mental health measurement resists clean metrics, why a PHQ 9 score starts a conversation but never finishes one, and why “scale” often flatters institutions more than it helps people. She breaks down how impact investing shapes care delivery, why schools need networked systems not slogans, and why friction might be developmentally necessary.The stakes are real. Vulnerable families navigate snake oil, glossy apps, and pay to play algorithms while carrying the burden of choice in crisis. Benghiat lives inside that complexity and refuses to simplify it.RELATED LINKSRebecca BenghiatInner FoundationAspen Ideas HealthThe Jed FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At age 12, Dr. Chrystal Starbird stood by a pond after turning her mother in to the police. She watched tadpoles and fish move beneath the surface and found a strange kind of order. Science became her refuge long before it became her career. Years later, she built that refuge into a profession. She now serves as an Assistant Professor at the University of North Carolina, studies structural biology tied to cancer and Alzheimer's disease, and won Cell's first Rising Black Scientist Award in 2020. On paper, she fits the model of success. In practice, she had to fight for basic access at every stage.Conference travel required upfront cash she did not have. Networking favored pedigree over merit. Mentorship often depended on who knew your name in the room. Chrystal learned those rules, then chose to break them open for others.Oliver Bogler examines what Chrystal calls the advocacy tax. She has delivered over 70 invited talks. Nearly 40 percent focus on equity, mentorship, and policy. Academic reward systems do not count that labor toward tenure. She still does it.Through her leadership at the Life Science Editors Foundation, Chrystal helped build the JEDI program, which pairs underrepresented scientists with editors from journals like Cell and Nature. The program has supported over 100 awardees with more than 1,000 hours of mentorship. This episode exposes how biomedical science rewards output while ignoring the work required to make the system accessible. It also shows what happens when the people most affected refuse to step back.RELATED LINKSDr. Chrystal StarbirdStarbird LabLife Science Editors FoundationJEDI ProgramFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At 19, Jansher Naim went from sharp stomach pain to a Stage 4 fibrolamellar diagnosis that few doctors see and even fewer young adults survive. He pushed through 41 rounds of chemotherapy, a Whipple surgery, and months of isolation while his friends kept moving through normal college life. In the studio, Jansher sits beside his mother Sadia Siddiqui, who refused early defeat and helped overhaul his care team when the first plan offered little optimism. Now a Computer Science student at Columbia, Jansher lives in the uneasy space between remission and risk, managing fertility decisions, travel for ongoing care, and the strange pressure to look fine at 22. Together they describe what it takes to grow up fast inside a system that rarely knows what to do with young adults who refuse to disappear.RELATED LINKSJansher NaimSadia SiddiquiFibroFighters FoundationColumbia UniversityFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jessica Federer built her career inside the rooms where science, money, and power collide. As the first female Chief Digital Officer at Bayer, she helped steer a 120,000 person global company through the rise of digital medicine while confronting a harder truth: women were excluded from U.S. clinical trials until 1993. In this conversation, she explains how decades of “first in man” research shaped drug development, why women experience side effects at nearly 2x the rate of men, and how guidance on sex based differences did not arrive from the FDA until December 2025. She shares what it means to sit on a Yale Institutional Review Board, why clinical trial stipends over $3,000 get taxed, and why she believes participants deserve tax credits instead. From GLP 1 profits to $40,000,000 women's health funds that barely move the needle, this episode names the gaps and the opportunity hiding inside them. RELATED LINKSJessica Federer on LinkedInJessica Federer on InstagramYale School of Public HealthHealth of Women Investor SummitFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.